midostaurin
Selected indexed studies
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. (N Engl J Med, 2017) [PMID:28644114]
- Midostaurin. (, 2012) [PMID:31644181]
- Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. (Leukemia, 2021) [PMID:33654204]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. (2017) pubmed
- Midostaurin. (2012) pubmed
- Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. (2021) pubmed
- Midostaurin: First Global Approval. (2017) pubmed
- Midostaurin in Advanced Systemic Mastocytosis: A Systematic Review and Meta-analysis. (2023) pubmed
- Midostaurin approved for FLT3-mutated AML. (2017) pubmed
- Beyond midostaurin: Which are the most promising FLT3 inhibitors in AML? (2019) pubmed
- Midostaurin for the management of FLT3-mutated acute myeloid leukemia and advanced systemic mastocytosis. (2019) pubmed
- Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis. (2017) pubmed
- Midostaurin in acute myeloid leukemia: current evidence and practical considerations in routine clinical use. (2020) pubmed